Bacterial overgrowth syndrome. Clinical presentation
Clinical review for general practice · 19.06.2026 · 7 (4) · 25-30
DOI: 10.47407/kr2026.7.4.00814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 19.06.2026. Verfasst von Inna G Pakhomova.
Abstract (Originalsprache)
Bacterial overgrowth syndrome (BOS) is an important problem, since its course is associated with the symptoms typical for many gastrointestinal tract (GIT) disorders, it is diagnosed late and has a significant impact on the patients’ quality of life. BOS is more often found in individuals with chronic noncommunicable diseases. BOS is a disorder characterized by the abnormal small intestinal microbiota composition manifested by the intestinal motility alteration, malabsorption and accompanied by disruption of the local and systemic immune response. Microbial landscapes of different sections of the small intestine (duodenum, jejunum, and ileum) show differences in the ratios of microbial representatives belonging mostly to the type Firmicutes. This is due to the fact that the living conditions of microbial cells change as we move from the proximal to the distal part of the intestine. Excessive bacterial load in the small intestine determining the BOS development is generated mostly by gram-negative aerobes and anaerobes. The conditions, in which the physiological elimination of excess bacteria in the small intestine is disrupted and/or favorable conditions for bacterial proliferation are created, represent the BOS risk factors. The BOS prolonged course without therapeutic adjustment can result in the malabsorption syndrome. The complaints of frequent bloating, abdominal pain, diarrhea or constipation, which can occur in various GIT and other disorders, represent the features of the disease pattern. Therefore, the thoroughly collected complaints, patient’s medical history and clinical features allow one to timely prescribe the necessary additional BOS diagnosis and start treatment. Rifaximin, a non-absorbable enteric antibiotic, the most studied in terms of BOS treatment, represents the first-line therapy for BOS. Its advantages over systemic antibiotics are low absorption in the GIT (below 0.4%), low rate of systemic side effects, as well as low risk of the emergence of bacterial strains resistant to systemic antibacterial drugs and intestinal antimicrobial drugs. The paper presents the review of literature about the BOS causes and mechanisms, as well as diagnosis and treatment options. A clinical case of a female patient with BOS is provided. Keywords: bacterial overgrowth syndrome, bloating, rifaximin, belching.
Zitieren
APA
Pakhomova, I. G. (2026). Bacterial overgrowth syndrome. Clinical presentation. Clinical review for general practice, 7(4), 25-30. https://doi.org/10.47407/kr2026.7.4.00814
Vancouver
Pakhomova IG. Bacterial overgrowth syndrome. Clinical presentation. Clinical review for general practice. 2026;7(4):25-30. doi:10.47407/kr2026.7.4.00814
BibTeX
@article{Pakhomova2026,
author = {Pakhomova, Inna G},
title = {Bacterial overgrowth syndrome. Clinical presentation},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {4},
pages = {25--30},
doi = {10.47407/kr2026.7.4.00814}
}
EUVIMED